Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.
BACKGROUND: In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy. METHODS: This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory. RESULTS: Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological. CONCLUSIONS: In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.
Authors
- Xavier Tréton (ORCID: https://orcid.org/0000-0001-8123-9213)
- Marc Harb (ORCID: https://orcid.org/0009-0006-3548-8749)
- Thomas Bazin (ORCID: https://orcid.org/0000-0002-3262-3902)
- Alexandre Nuzzo (ORCID: https://orcid.org/0000-0002-8952-7620)
- Carmen Stefanescu
- Francisca Joly
- Lara Ribeiro
- Yoram Bouhnik
- Teodor Berea
Institutions
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Hôpital Beaujon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/ibd/izag222
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00